Meanwhile, we found that treatment of cells with anti-CCL2 antibody only partially inhibited the LN-metastatic capability of the control bladder cancer cells (the ratio of metastatic LNs from 37.50% reduced to 25.00%) but strongly inhibited the LN-metastatic capability of LNMAT1-overexpressing cells (the ratio of metastatic LNs from 93.75% reduced to 18.75%) (Supplementary Fig. 6c). Here, DUXAP9 is linked to urinary bladder cancer.